Apellis Pharmaceuticals, Inc. 4

Alec Machiels’ direct and indirect Apellis common shares and in-the-money stock options were cashed out at $41.00 per share plus CVRs (or cancelled if out-of-the-money) in connection with Biogen’s acquisition of Apellis on May 14, 2026.

On May 14, 2026, in connection with the closing of Biogen Inc.’s acquisition of Apellis Pharmaceuticals, Inc., reporting person Alec Machiels had all of his direct and indirect holdings of Apellis common stock and stock options effectively converted or cancelled pursuant to the merger agreement. All directly held and indirect common shares (including those held via Bauhaus 1 LLC, by his spouse, and in his spouse’s trust) were exchanged into the right to receive $41.00 in cash per share plus one contingent value right (CVR) per share, with potential additional cash of up to $4.00 per CVR upon future milestones. Vested in-the-money stock options with exercise prices below $41.00 were automatically cancelled and converted into cash equal to the spread between $41.00 and the respective exercise prices, plus one CVR for each underlying share, while options with exercise prices at or above $45.00 were cancelled without consideration. Following these transactions triggered by the merger, Machiels no longer holds Apellis equity securities, as the company became a wholly owned subsidiary of Biogen.

Filing Facts

CIK

1492422

Ticker

APLS

Form

4

Source Type

sec

Accession

0001193125-26-224611

Alert Tier

6